Share on StockTwits

Dipexium Pharmaceuticals (NASDAQ:DPRX) released its earnings data on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.09, Stock Ratings reports.

On the ratings front, analysts at Feltl & Co. initiated coverage on shares of Dipexium Pharmaceuticals in a research note on Wednesday, May 28th. They set a “strong-buy” rating and a $21.75 price target on the stock.

Shares of Dipexium Pharmaceuticals (NASDAQ:DPRX) opened at 8.97 on Wednesday. Dipexium Pharmaceuticals has a 52-week low of $8.00 and a 52-week high of $15.86. The stock’s 50-day moving average is $9.39 and its 200-day moving average is $9.82. The company’s market cap is $76.6 million.

Dipexium Pharmaceuticals, Inc, formerly Dipexium Pharmaceuticals, LLC, is a pharmaceutical company. The Company is focused on the development and commercialization of Locilex.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.